Search the site

Respiratory Illnesses

Coming up in 2021 We have a a study to suit every age range in 2021! From babies at just six weeks for the FluBub Study, through to teenagers in

CMVictory Study

The CMVictory Study aims to learn more about the safety and effectiveness of a potential CMV vaccine.

ComboVax Study

We are looking for children and teenagers to take part in an important study investigating the effectiveness of a new combination booster vaccine designed to protect against tetanus, diphtheria, pertussis (whooping cough) and polio.

The Western Australian Influenza Vaccine Effectiveness Study (WAIVE)

The main objectives were to evaluate effectiveness of the annual flu vaccine in young children, and the burden of flu on young children and their families.

Meningococcal Disease

MenABCWY QUINTET Study Meningococcal disease is a rare but serious disease that can result in death if not recognised and treated quickly. There are

PAEDS - Paediatric Active Enhanced Surveillance

The PAEDS Study monitors childhood conditions of public health importance that are difficult to effectively capture through other surveillance mechanisms.

Research

Yarning with a remote Aboriginal community about the next steps for achieving healthy skin

Skin health is widely recognised as being important for overall good health and well-being, yet the burden of skin infections in remote Aboriginal communities remains high. This project aimed to explore if virtual support for skin health could be a strategy to reduce community barriers to skin health engagement.

Research

Interactions between bacteria in the human nasopharynx: a scoping review

Emerging evidence indicates that interactions between bacteria shape the nasopharyngeal microbiome and influence respiratory health. This Review uses the systematic scoping methodology to summarise 88 studies including observational and experimental studies, identifying key interactions between bacteria that colonise the human nasopharynx.

Research

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents

This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents.